3-(3-(4-((pyridin-2-yloxy)methyl)benzyl)isoxazol-5-yl)pyridin-2-amine and Candidiasis--Invasive

3-(3-(4-((pyridin-2-yloxy)methyl)benzyl)isoxazol-5-yl)pyridin-2-amine has been researched along with Candidiasis--Invasive* in 1 studies

Other Studies

1 other study(ies) available for 3-(3-(4-((pyridin-2-yloxy)methyl)benzyl)isoxazol-5-yl)pyridin-2-amine and Candidiasis--Invasive

ArticleYear
The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:1

    The in vitro and in vivo activity of the inositol acyltransferase inhibitor E1210 was evaluated against echinocandin-resistant Candida albicans. E1210 demonstrated potent in vitro activity, and in mice with invasive candidiasis caused by echinocandin-resistant C. albicans, oral doses of 10 and 40 mg E1210/kg of body weight twice daily significantly improved survival and reduced fungal burden compared to those of controls and mice treated with caspofungin (10 mg/kg/day). These results demonstrate the potential use of E1210 against resistant C. albicans infections.

    Topics: Aminopyridines; Animals; Antifungal Agents; Candida albicans; Candidiasis, Invasive; Caspofungin; Dose-Response Relationship, Drug; Drug Resistance, Fungal; Echinocandins; Fluconazole; Isoxazoles; Lipopeptides; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests

2015